Compared with other treatment approaches, definitive surgical extirpation provides the best survival outcomes in patients with invasive, non-urachal adenocarcinoma of the bladder, results of a recent study suggest.
Errors related to bladder cancer site and symptom codes could lead to take backs.
"While there was no further reduction of prostate cancer risk after finasteride was discontinued, there was also no evidence that stopping finasteride resulted in more cases of prostate cancer," writes Badar M. Mian, MD.
“I hope we can continue to improve ERAS, but it’s already a significant advance,” says one urologist.
Retrospective cohort study identifies wide variation in treatment rates, spending.
Evidence suggests fallopian tube removal will lead to reduced ovarian cancer incidence.
Large or small, your ‘call center’ is essential to a good first impression.
Several strategies are available, each with their own pros and cons.
Both the efficacy and safety of abiraterone acetate (ZYTIGA) treatment for metastatic castrate-resistant prostate cancer (mCRPC) appear to differ depending on race, according to results of Abi Race, a prospective, multicenter trial presented at the American Society of Clinical Oncology annual meeting in Chicago.